Essential Partners’s Neumora Therapeutics NMRA Stock Holding History

Essential Partners’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$178	Buy	+299	New	+$414	﹤0.01%	2619
2026 Q1	–	Sell	-30	Closed	-$54	–	2946
2025 Q4	$54	Sell	30 -660	-96%	-$1.45K	﹤0.01%	2629
2025 Q3	$1.26K	Sell	690 -450	-39%	-$727	﹤0.01%	1953
2025 Q2	$836	Buy	+1,140	New	+$864	﹤0.01%	1558

Other funds holding NMRA

LPT

Legacy Private Trust Neenah, Wisconsin $1.83B AUM 13% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners's NMRA Position: Q3 2026 in Review

Essential Partners opened a new position in Neumora Therapeutics (NMRA) in Q3 2026: 299 shares worth $178. The stake represents ﹤0.01% of the portfolio and ranks #2619 among its holdings. This is a return to the name: Essential Partners previously reported a position in NMRA as recently as Q4 2025.

Essential Partners first reported a position in NMRA in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.26K in Q3 2025. 6 funds tracked by Wall St. Rank hold NMRA as of Q3 2026.

Essential Partners held 299 shares of Neumora Therapeutics worth $178 as of Q3 2026.
Neumora Therapeutics was a new Essential Partners position in Q3 2026.
Neumora Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2619 holding.
Essential Partners first reported a position in Neumora Therapeutics in Q2 2025 and has held it in 4 quarters since.
Essential Partners's Neumora Therapeutics position peaked at $1.26K in Q3 2025.
6 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.